RBC Capital analyst Brian Abrahams said he believes weakness related to a news article discussing the departure of George Golumbeski from Celgene is "unfounded," as his understanding based on talks with the company and LinkedIn info is that Rob Hershberg has already been running business development at the company for over a year and that Golumbeski had transitioned to more of a strategic role prior to his exit. Given the transition was in the works for some time, he does not see any relation between reports about this emerging today and proximity to upcoming readouts, said Abrahams, who keeps an Outperform rating on Celgene shares.